|
| Protease nexin 1: a novel regulator of prostate cancer cell growth and neoangiogenesis |
|
https://doi.org/10.18632/oncotarget.824
Chad M. McKee, Danmei Xu, and Ruth J. Muschel
|
| 1-2 |
|
| Targeting glycogen metabolism: a novel strategy to inhibit cancer cell growth |
|
https://doi.org/10.18632/oncotarget.841
Elena Favaro, and Adrian L. Harris
|
| 3-4 |
|
| The limited contribution of DNA methylation to PMLRARα induced leukemia |
|
https://doi.org/10.18632/oncotarget.875
Christian Rohde, Till Schoofs, and Carsten Müller-Tidow
|
| 5-6 |
|
| New concepts for CML clonality |
|
https://doi.org/10.18632/oncotarget.882
Jamshid S. Khorashad, Michael W. Deininger, and Thomas O’Hare
|
| 7-8 |
|
| MET amplification as a potential therapeutic target in gastric cancer |
|
https://doi.org/10.18632/oncotarget.718
Hisato Kawakami, Isamu Okamoto, Tokuzo Arao, Wataru Okamoto, Kazuko Matsumoto, Hirokazu Taniguchi, Kiyoko Kuwata, Haruka Yamaguchi, Kazuto Nishio, Kazuhiko Nakagawa, and Yasuhide Yamada
|
| 9-17 |
|
| KDM1 is a novel therapeutic target for the treatment of gliomas |
|
https://doi.org/10.18632/oncotarget.725
Gangadhara R Sareddy, Binoj C. Nair, Samaya K Krishnan, Vijay K Gonugunta, Quan-guang Zhang, Naoki Miyata, Takayoshi Suzuki, Andrew Brenner, Darrell W Brann, and Ratna K Vadlamudi
|
| 18-28 |
|
| Functional analysis of nonhotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine |
|
https://doi.org/10.18632/oncotarget.755
Kyung H Yi, Jossette Axtmayer, John P Gustin, Anandita Rajpurohit, and Josh Lauring
|
| 29-34 |
|
| SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large BCell Lymphoma DLBCL Patients |
|
https://doi.org/10.18632/oncotarget.774
Birgit Schif, Jochen K Lennerz, Christian W Kohler, Markus Kreuz, Stefan Bentink, Ingo Melzner, Olga Ritz, Lorenz Trümper, Markus Löffler, Rainer Spang, and Peter Möller
|
| 35-47 |
|
| Highthroughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion |
|
https://doi.org/10.18632/oncotarget.756
Laura Lehtinen, Kirsi Ketola, Rami Mäkelä, John-Patrick Mpindi, Miro Viitala, Olli Kallioniemi, and Kristiina Iljin
|
| 48-63 |
|
| Enhancing the Efficacy of Drugloaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy |
|
https://doi.org/10.18632/oncotarget.777
Brian C. Baumann, Gary D. Kao, Abdullah Mahmud, Takamasa Harada, Joe Swift, Christina Chapman, Xiangsheng Xu, Dennis E. Discher, and Jay F. Dorsey
|
| 64-79 |
|
| Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition |
|
https://doi.org/10.18632/oncotarget.793
Pooja Mohan, Joan Castellsague, Jihong Jiang, Kristi Allen, Helen Chen, Oksana Nemirovsky, Melanie Spyra, Kaiji Hu, Lan Kluwe, Miguel Angel Pujana, Alberto Villanueva, Victor F. Mautner, Jonathan J. Keats, Sandra E. Dunn, Conxi Lazaro, and Christopher A. Maxwell
|
| 80-93 |
|
| Intraductal Delivery of Adenoviruses Targets Pancreatic Tumors in Transgenic Elamyc Mice and Orthotopic Xenografts |
|
https://doi.org/10.18632/oncotarget.795
Anabel José, Luciano Sobrevals, Juan Miguel Camacho-Sánchez, Meritxell Huch, Núria Andreu, Eduard Ayuso, Pilar Navarro, Ramon Alemany, and Cristina Fillat
|
| 94-105 |
|
| Quantification of Mesenchymal Stem Cells MSCs at Sites of Human Prostate Cancer |
|
https://doi.org/10.18632/oncotarget.805
W. Nathaniel Brennen, Shuangling Chen, Samuel R. Denmeade, and John T. Isaacs
|
| 106-117 |
|
| Dual EGFR inhibition in combination with antiVEGF treatment: A phase I clinical trial in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.763
Gerald S. Falchook, Aung Naing, David S. Hong, Ralph G. Zinner, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Sonia K. Morgan-Linnell, Yunfang Jiang, Christel C. Bastida, Jennifer J. Wheler, and Razelle Kurzrock
|
| 118-127 |
|
| Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention |
|
https://doi.org/10.18632/oncotarget.786
Meiyun Fan, Susan R. Pfeffer, Henry T. Lynch, Pamela Cassidy, Sancy Leachman, Lawrence M. Pfeffer, and Levy Kopelovich
|
| 128-141 |
|
| Ras inhibition enhances autophagy which partially protects cells from death |
|
https://doi.org/10.18632/oncotarget.703
Eran Schmukler, Efrat Grinboim, Sari Schokoroy, Adva Amir, Eya Wolfson, Yoel Kloog, and Ronit Pinkas-Kramarski
|
| 142-152 |
|
| Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials |
|
https://doi.org/10.18632/oncotarget.832
Ishwaria Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, Aung Naing, Ahmed Kaseb, Javle Milind, Siqing Fu, David S Hong, Sarina Piha-Paul, Jenifer Wheler, Kenneth Hess, Filip Janku, Gerald Falchook, Robert A Wolff, and Razelle Kurzrock
|
| 153-162 |
|
| TIMP2 modulates cancer cell transcriptional profile and enhances Ecadherin/betacatenin complex expression in A549 lung cancer cells |
|
https://doi.org/10.18632/oncotarget.801
Dimitra Bourboulia, HuiYing Han, Sandra Jensen-Taubman, Noah Gavil, Biju Isaac, Beiyang Wei, Len Neckers, and William Stetler-Stevenson
|
| 163-173 |
